Comparative Pharmacology
Head-to-head clinical analysis: LARTRUVO versus MATULANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARTRUVO versus MATULANE.
LARTRUVO vs MATULANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olaratumab is a recombinant human IgG1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.
None Documented
None Documented
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Terminal elimination half-life is approximately 7-10 hours (range 5-15 hours) in adults; context: prolonged in hepatic or renal impairment.
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Primarily renal (approximately 50-60% as unchanged drug and metabolites) and fecal (approximately 10-20%); minor biliary excretion.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent